The Food and Drug Administration said it had not yet received a final report on the study, called Enhance. The agency's review will take about six months after the final report is received, the FDA said.
WASHINGTON (Reuters) - U.S. health officials said on Friday they would review whether to take regulatory action over Merck & Co Inc and Schering-Plough's cholesterol medicine Vytorin following the drug's failure to work better than a generic drug in a study of plaque build-up in neck arteries.
The Food and Drug Administration said it had not yet received a final report on the study, called Enhance. The agency's review will take about six months after the final report is received, the FDA said.
(Reporting by Lisa Richwine; Editing by Tim Dobbyn)
